TD Private Client Wealth LLC Lowers Stock Position in Encompass Health Co. (NYSE:EHC)

TD Private Client Wealth LLC decreased its holdings in Encompass Health Co. (NYSE:EHC) by 66.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,485 shares of the company’s stock after selling 4,851 shares during the period. TD Private Client Wealth LLC’s holdings in Encompass Health were worth $229,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. State Street Corp grew its position in shares of Encompass Health by 0.7% in the 3rd quarter. State Street Corp now owns 3,025,769 shares of the company’s stock worth $292,410,000 after buying an additional 21,329 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Encompass Health by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after acquiring an additional 20,547 shares in the last quarter. Copeland Capital Management LLC raised its position in shares of Encompass Health by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock valued at $119,418,000 after purchasing an additional 8,548 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Encompass Health by 16.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 888,827 shares of the company’s stock worth $82,083,000 after purchasing an additional 128,331 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in Encompass Health by 2,458.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after purchasing an additional 835,135 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Up 0.8 %

Shares of Encompass Health stock opened at $100.71 on Wednesday. Encompass Health Co. has a fifty-two week low of $76.11 and a fifty-two week high of $104.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The company has a market cap of $10.14 billion, a P/E ratio of 22.58, a price-to-earnings-growth ratio of 2.31 and a beta of 0.92. The firm has a 50-day simple moving average of $98.28 and a two-hundred day simple moving average of $97.26.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, equities analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.68%. Encompass Health’s dividend payout ratio (DPR) is 15.25%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on EHC shares. Royal Bank of Canada reiterated an “outperform” rating and set a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. Barclays increased their price objective on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. KeyCorp lifted their target price on Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Encompass Health has an average rating of “Buy” and an average target price of $107.67.

Insider Transactions at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.10% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.